Site last updated:
December 2011
Cancer Services Forum currently has 1452 registered members
New cancer medicines: Joint working between the NHS and the pharmaceutical industry
Share
Industry perspective: UK oncology market
Amanda Cunnington (Head of Healthcare Development, Roche Products Ltd) gave an industry perspective on the UK health market, covering such topics as drug access, marketing and the challenges faced in preparing submissions to NICE and other regulatory bodies.
Drug pricing in the UK: Are risk-share schemes here to stay?
During this session the floor was shared by Allan Karr and Eric Bokmans.
Mr Karr (Pharmacy Business Services Manager, University College London Hospital) has worked in pharmaceutical procurement for many years and is part of the national group that looks at contracting drugs for the NHS. He talked the delegates through how drug prices are set in the UK, looking at the Pharmaceutical Price Regulation Scheme (PPRS) and how this impacts on drug prices and what that means for access to medicines for cancer patients.
Dr Karr then talked about PASs and how they have been growing, particularly in the area of oncology medicines, rendering drugs that might not otherwise be cost effective accessible on the NHS. He talked through some of the many challenges that these schemes have posed, mentioning, for example, administrative burden and poor reimbursement strategies.
Page 5 of 14
Discussion.